OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← All Supported Cancers

Cutaneous & Mucosal Melanoma — Options & Clinical Trial Reference

Source-cited reference covering BRAF V600 status, NRAS/KIT, nodal staging, neoadjuvant/adjuvant and checkpoint/targeted therapy categories, and recruiting trials.

Module v6.0.0 · Curated SHA-256: 47ba5c2e2c1931eb · Trial Snapshot: 2026-11-15

Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesbiomarkers

Unranked Guideline & FDA-Label Option Categories (36 total)

Option / PathwayCategoryPrimary Sources
Surgery and regional-node staging review
Review the recorded primary pathology, whether the definitive wide excision has been done, regional nodes and the need for a sentinel-node discussion. NCI summary for stage IA: “Excision with or without sentinel lymph node biopsy (SLNB).”
Local carenci-melanoma, nci-melanoma-pdq-2025
Post-resection surveillance discussion
Plan individualized clinical, skin and regional-node follow-up; observation remains an explicit discussion.
Follow-upnci-melanoma
Adjuvant pembrolizumab
Discuss postoperative anti-PD-1 therapy in the supported completely resected setting.
Systemic therapykeytruda-label, keynote716, kn716-final, kn054-7y
Adjuvant nivolumab
Discuss postoperative nivolumab after complete resection.
Systemic therapyopdivo-label, checkmate76k, checkmate238, cm76k-primary, cm238-9y, cm238-correction
Adjuvant dabrafenib plus trametinib
Discuss adjuvant BRAF/MEK inhibition for confirmed BRAF V600E disease.
Systemic therapytafinlar-label, mekinist-spl, combiad-final
Review discordant adjuvant BRAF V600K evidence
Reconcile the broader US label with the guideline caution before any targeted adjuvant choice.
Specialist reviewtafinlar-label, combiad-final
Neoadjuvant nivolumab plus ipilimumab, then response-guided review
Discuss the NADINA strategy before surgery in macroscopic nodal stage III disease.
Systemic therapynadina, opdivo-label
Perioperative pembrolizumab
Discuss preoperative and postoperative pembrolizumab for clinically detectable, resectable disease.
Systemic therapys1801, keytruda-label
Upfront surgery followed by adjuvant-treatment review
Discuss complete local treatment followed by an explicit postoperative systemic-treatment decision.
Local carenci-melanoma, nadina, s1801
Nivolumab plus ipilimumab
Discuss combined PD-1/CTLA-4 blockade in untreated advanced cutaneous melanoma.
Systemic therapyopdivo-label, checkmate067-final, dreamseq, nct01844505
Nivolumab plus relatlimab
Discuss combined PD-1/LAG-3 blockade in untreated advanced disease.
Systemic therapyopdualag-label, relativity047
Nivolumab monotherapy
Discuss single-agent PD-1 treatment.
Systemic therapyopdivo-label, checkmate067-final, relativity047, nct01844505
Pembrolizumab monotherapy
Discuss single-agent pembrolizumab.
Systemic therapykeytruda-label, kn006-10y, nct01866319
Dabrafenib plus trametinib
Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant.
Systemic therapytafinlar-label, mekinist-spl, dreamseq
Encorafenib plus binimetinib
Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant.
Systemic therapymektovi-label, braftovi-spl, mektovi-spl, columbus-7y

View all 36 Cutaneous & Mucosal Melanoma reference options →

Recruiting Clinical Trials (32 curated)

NCT IDStudy TitlePhase
NCT01638676A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsPHASE1/PHASE2
NCT02621021A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabPHASE2
NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersPHASE1/PHASE2
NCT03567889Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsPHASE3
NCT03842943Neoadjuvant Combination Immunotherapy for Stage III MelanomaPHASE2
NCT03947385Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2
NCT04119024Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsPHASE1
NCT04511013A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPHASE2
NCT04594187Nodal Radiation Therapy for Sentinel Lymph Node Positive MelanomaPHASE2
NCT04787042Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2
NCT04844528Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin CancersPHASE2
NCT04895709A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPHASE1/PHASE2

View all 32 Cutaneous & Mucosal Melanoma clinical trials →